MDACC Study No:2007-0965 ( NCT No: NCT00607997)
Title:A Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Voreloxin Injection in Patients Greater than or Equal to 60 Years of Age with Previously Untreated Acute Myeloid Leukemia
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:Voreloxin
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if voreloxin injection
(voreloxin) (formerly known as SNS-595 injection) can help to control AML in
patients 60 years of age and older who have not received any other treatment
for cancer. The safety of this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Voreloxin
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:Hospitalization is not required for treatment. while on this study.
Supported By:Sunesis Pharmaceuticals Inc.
Return Visit:Patients will be seen weekly while on study. Patients with a CR or CRp at the
End-of-Treatment Visit return to the clinical site every 287 days for 1 year,
then every 56+/-14 days thereafter for up to 1 year to confirm duration of
Home Care:None

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults